AACR Annual Meeting

Dr Roberto Borea explores how BMI impacts NSCLC survival and molecular pathways, revealing key T-cell and redox data for IO and TKI treatment cohorts.

A new Bayesian statistical framework uses the residual cancer burden score to better predict long-term survival in breast cancer trials beyond binary pCR.

With long-term follow-up, HLA-A*02:01–positive patients with metastatic uveal melanoma maintained survival benefit with the bispecific agent vs investigator's choice.

Bayesian modeling links residual cancer burden shifts to survival, helping neoadjuvant breast cancer trials and FDA approvals predict real benefit.

mRNA-4359 demonstrated high response rates and antigen-specific T-cell activation in a small cohort of previously untreated patients.

Dr Bazhenova presents TRUST data at AACR 2026, showing taletrectinib reached a 46.1-month PFS and 89.8% ORR in TKI-naive, ROS1-positive metastatic NSCLC.

A brain-penetrant pan-RAF/MEK molecular glue demonstrated a 38% response rate in a heavily pretreated melanoma population that currently has no approved targeted therapies.

A post hoc analysis shows significantly improved ORR and PFS in advanced NSCLC with higher AFM24 exposure, supporting optimized dosing strategies.

Ahmad Tarhini, MD, PhD, provides data into his research looking at inherited genetic variations and genetic ancestry in patients with high-risk melanoma.

Adagrasib shows initial promise, tolerability, and encouraging response rates in STK11/KRAS G12C-mutant lung cancer.

Ravindra Uppaluri, MD, PhD, discussed the KEYNOTE-689 trial, which investigated pembrolizumab in locally advanced head and neck squamous cell carcinoma.

Ahmad Tarhini, MD, PhD, discusses inherited genetic variations and genetic ancestry, particularly for patients with high-risk melanoma.

Invikafusp alfa elicited clinically meaningful antitumor activity in patients with advanced solid tumors resistant to anti–PD-1/PD-L1 agents.

Runimotamab plus trastuzumab resulted in positive clinical activity and tolerability over runimotamab alone in patients with HER2-positive breast cancer.

Updated findings from a phase 2 study investigating the IL-2–binding monoclonal antibody AU-007 show a manageable safety profile with strong antitumor evidence.

Phase 1b Beamion LUNG-1 trial data at AACR 2025 showed zongertinib yielded responses in pretreated HER2-mutant NSCLC, including TKD and non-TKD mutations.

Pembrolizumab combo before/after surgery and radiation significantly improved event-free survival in resectable advanced head and neck cancer per KEYNOTE-689, introducing a potential new standard of care.

Based on the encouraging efficacy signals of SOT101 plus pembrolizumab in these heavily pretreated patients with advanced solid tumors in the AURELIO-03 study, the AURELIO-04 trial is planned.

Molecular characteristics associated with resistance to CD19-directed chimeric antigen receptor T-cell therapy for pediatric acute lymphoblastic leukemia can hopefully improve patient selection and eligibility for therapy.

Promising T-cell responses and safety has been shown with the CoVac-1 vaccine in patients with cancer who have disease- or treatment-related immunoglobulin deficiency.

Results from a post-hoc exploratory analysis of the TALAPRO-1 study signal that high genomic loss of heterozygosity may be assiciated with enhanced response to talazoparib in patients with metastatic castration-resistant prostate cancer.

Findings of CheckMate 816 show improved event-free survival and partial complete response and promising overall survival results with the use of neoadjuvant nivolumab in combination with chemotherapy for patients with resectable NSCLC.

Results from the phase 2 CheckMate-848 study show that nivolumab in combination and ipilimumab may be effective for the treatment of advanced or metastatic tumor mutational burden–high solid tumors that were refractory to standard therapies.

According to new data, different dosing strategies of elimusertib for advanced solid tumors with ATM alterations and other DNA damage repair gene defects has demonstrated early efficacy.

Sotorasib continues to wow in the phase 1/2 CodeBreaK 100 trial of patients with KRAS G12C–mutant non–small cell lung cancer.

According to Tanjina Kader, PhD, 12% of patients in the cohort who developed new, independent primary tumors raised the question of whether using these genetic biomarkers for prediction of recurrence is a good idea.

Preclinical research indicates that anti-mesothelin chimeric antigen receptor T cells may be more effective than gavocabtagene autoleucel in mesothelin-expressing tumors.

Prolonged periods of radiographic and clinical improvement in children and young adults with H3K27M diffuse intrinsic pontine gliomas and spinal diffuse midline gliomas has been shown with GD2-directed chimeric antigen receptor T cells.

The bispecific antibody therapy AMF13 combined with preactivated and expanded natural killer cells showed encouraging activity in patients with heavily pretreated lymphoma.